Triazavirin

Triazavirin (TZV, Riamilovir) is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical. It has a novel triazolotriazine core, which represents a new structural class of non-nucleoside antiviral drugs.[1]

Triazavirin
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.217.074
Chemical and physical data
FormulaC5H4N6O3S
Molar mass228.189 g·mol−1
3D model (JSmol)

Uses

It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti-influenza activity.[2][3][4] However triazavirin has also been found to have antiviral activity against a number of other viruses including Tick-borne encephalitis virus,[5] and Forest-Spring Encephalitis virus,[6] and is also being investigated for potential application against Lassa fever and Ebola virus disease.[7][8][9][10][11] In February 2020, testing of triazavirin was started against SARS-CoV-2.[12][13][14]

See also

References
  1. Rusinov VL, Sapozhnikova IM, Ulomskii EN, Medvedeva NR, Egorov VV, Kiselev OI, et al. (2015). "Nucleophilic substitution of nitro group in nitrotriazolotriazines as a model of potential interaction with cysteine-containing proteins". Chemistry of Heterocyclic Compounds. 51 (3): 275–280. doi:10.1007/s10593-015-1695-4. S2CID 83702396.
  2. Loginova SI, Borisevich SV, Maksimov VA, Bondarev VP, Kotovskaia SK, Rusinov VL, et al. (2007). "[Investigation of triazavirin antiviral activity against influenza A virus (H5N1) in cell culture]". Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic] (in Russian). 52 (11–12): 18–20. PMID 19275052.
  3. Karpenko I, Deev S, Kiselev O, Charushin V, Rusinov V, Ulomsky E, et al. (May 2010). "Antiviral properties, metabolism, and pharmacokinetics of a novel azolo-1,2,4-triazine-derived inhibitor of influenza A and B virus replication". Antimicrobial Agents and Chemotherapy. 54 (5): 2017–22. doi:10.1128/AAC.01186-09. PMC 2863629. PMID 20194696.
  4. Kiselev OI, Deeva EG, Mel'nikova TI, Kozeletskaia KN, Kiselev AS, Rusinov VL, et al. (2012). "[A new antiviral drug Triazavirin: results of phase II clinical trial]". Voprosy Virusologii (in Russian). 57 (6): 9–12. PMID 23477247.
  5. Loginova SI, Borisevich SV, Rusinov VL, Ulomskiĭ UN, Charushin VN, Chupakhin ON (2014). "[Investigation of Triazavirin antiviral activity against tick-borne encephalitis pathogen in cell culture]". Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic] (in Russian). 59 (1–2): 3–5. PMID 25051708.
  6. Loginova SY, Borisevich SV, Rusinov VL, Ulomsky EN, Charushin VN, Chupakhin ON, Sorokin PV (2015). "[Investigation of Therapeutic Efficacy of Triazavirin Against Experimental Forest-Spring Encephalitis on Albino Mice]". Antibiotiki I Khimioterapiia = Antibiotics and Chemoterapy [Sic] (in Russian). 60 (7–8): 11–3. PMID 26863736.
  7. "Target: Ebola". Pravda. 2014-12-22. Retrieved 18 January 2015.
  8. "Yekaterinburg pharmacies to sell domestic antiviral drug". Retrieved 18 January 2015.
  9. Cox S (2014-10-17). "Ebola crisis: Vaccine 'too late' for outbreak. BBC News, 17 October 2014". BBC News.
  10. Kukil Bora. Russia Will Begin Testing Triazavirin, Used For Lassa Fever, And Other Drugs On Ebola: Health Ministry. International Business Times, 12 November 2014
  11. Kezina, Darya (12 November 2014). "New antiviral drug from Urals will help fight Ebola and other viruses". Russia Beyond the Headlines.
  12. Jamshaid U (4 February 2020). "China Testing Russia's Triazavirin As Coronavirus Treatment". Russian Health Ministry. Urdupoint.
  13. "China Tests Russian Antiviral Drug Which Might Treat Coronavirus As Moscow Warns Of Possible 'Mass Outbreak'". 2020-02-05. Retrieved 11 February 2020.
  14. Wu, Xiaoke; Yu, Kaijiang; Wang, Yongchen; Xu, Wanhai; Ma, Hongli; Hou, Yan; Li, Yue; Cai, Benzhi; Zhu, Liying; Zhang, Min; Hu, Xiaoli; Gao, Jingshu; Wang, Yu; Qin, Huichao; Wang, Wenjie; Zhao, Mingyan; Wu, Xia; Zhang, Yong; Li, Lu; Li, Kang; Du, Zhimin; Mol, Ben Willem J.; Yang, Baofeng (2020). "Efficacy and safety of triazavirin therapy for coronavirus disease 2019: A pilot randomized controlled trial". Engineering. 6 (10): 1185–1191. doi:10.1016/j.eng.2020.08.011. ISSN 2095-8099. PMC 7476906. PMID 32923016. S2CID 221520816.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.